Adagio Medical Holdings, Inc (ADGM)

Adagio Medical closed a private placement in October 2025, raising approximately $19 million upfront, with the potential for an additional $31 million. The company announced the completion of enrollment for its FULCRUM-VT trial in October 2025, reporting preliminary results demonstrating 97% acute effectiveness. Adagio Medical reported a net loss of $10.1 million for the third quarter of 2025. Sean Salmon was appointed to Adagio Medical's Board of Directors in December 2025. Deborah Kaster increased her stake in the company by purchasing 15,000 shares in December 2025. Adagio Medical announced it had entered into a series of waivers with investors following a previous misstatement of financial results in January 2025. Marie-Claude Jacques was appointed as SVP of Global Sales and Antwan Gipson as SVP of Manufacturing and Operations in January 2026. Over the past six months, ADGM's stock price has decreased by approximately 26.34%.

Information regarding the specific demand seasonality for Adagio Medical Holdings, Inc.'s products and services is not publicly available.

Adagio Medical Holdings, Inc. specializes in Ultra-Low Temperature Cryoablation (ULTC) technology for treating cardiac arrhythmias. The iCLAS system is CE-marked for treating atrial fibrillation and flutter. The vCLAS ventricular ULTC catheter has FDA Breakthrough Device designation for ventricular arrhythmia treatment and is commercially available in Europe, but is investigational in the United States. The Cryopulse atrial PFCA catheter and accessories utilize pulsed-field cryoablation technology. The Adagio Ablation System uses cooled radiofrequency technology.

Adagio Medical Holdings, Inc. is developing and introducing its ablation technologies to the European Union (EU) market. Its devices are also sold to medical centers in the United States, the Asia-Pacific region, and internationally. The company's headquarters are located in Laguna Hills, California, United States.

Adagio Medical Holdings, Inc. maintains a neutral sentiment score of 5.4/10, with positive fund inflows. The FDA Breakthrough Device Designation for its vCLAS Cryoablation System and positive preliminary results from the FULCRUM-VT trial have positively contributed to its reputation. The company faced challenges, including a reported misstatement of financial results and an impending Nasdaq compliance issue. Leadership changes also occurred during this period.

Adagio Medical Holdings, Inc. has significant institutional ownership, with 17 institutional owners and shareholders holding a total of 11,685,330 shares. Key individual owners and insiders include CEO Todd Usen and Chief Financial Officer Deborah Kaster, both of whom have recently made insider purchases. Insiders collectively own approximately 1.4% of the company.